Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-contro...
Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial
About this item
Full title
Author / Creator
Ryan, Christopher W , Tangen, Catherine M , Heath, Elisabeth I , Stein, Mark N , Meng, Maxwell V , Alva, Ajjai S , Pal, Sumanta K , Puzanov, Igor , Clark, Joseph I , Choueiri, Toni K , Agarwal, Neeraj , Uzzo, Robert G , Haas, Naomi B , Synold, Timothy W , Plets, Melissa , Vaishampayan, Ulka N , Shuch, Brian M , Thompson, Ian M and Lara, Primo N
Publisher
England: Elsevier Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: Elsevier Ltd
Subjects
More information
Scope and Contents
Contents
Patients undergoing resection of renal cell carcinoma are at risk of disease relapse. We evaluated the effectiveness of the mammalian target of rapamycin inhibitor everolimus administered after surgery.
In this randomised, double-blind, phase 3 trial, we enrolled adults with histologically confirmed renal cell carcinoma who had undergone a full...
Alternative Titles
Full title
Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial
Authors, Artists and Contributors
Author / Creator
Tangen, Catherine M
Heath, Elisabeth I
Stein, Mark N
Meng, Maxwell V
Alva, Ajjai S
Pal, Sumanta K
Puzanov, Igor
Clark, Joseph I
Choueiri, Toni K
Agarwal, Neeraj
Uzzo, Robert G
Haas, Naomi B
Synold, Timothy W
Plets, Melissa
Vaishampayan, Ulka N
Shuch, Brian M
Thompson, Ian M
Lara, Primo N
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10622111
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10622111
Other Identifiers
ISSN
0140-6736,1474-547X
E-ISSN
1474-547X
DOI
10.1016/S0140-6736(23)00913-3
